Vyome Holdings (HIND) Change in Receivables (2015 - 2025)
Vyome Holdings (HIND) posted quarterly Change in Receivables of -$307293.0 for Q3 2025, down 180.75% year-over-year from $380532.0 in Q3 2024, and down 147.35% quarter-over-quarter from $649000.0 in Q2 2025.
Vyome Holdings (HIND) Change in Receivables (2015 - 2025) Analysis & Trends
Vyome Holdings' Change in Receivables history runs 10 years deep, the most recent figure standing at -$307293.0 for Q3 2025.
- In Q3 2025, Change in Receivables fell 180.75% year-over-year to -$307293.0; the TTM figure through Sep 2025 stood at -$472825.0 (up 22.93% YoY), while the FY2024 annual figure was -$560000.0, down 348.0% from the prior year.
- Change in Receivables for Q3 2025 stood at -$307293.0, down from $649000.0 in the prior quarter.
- The five-year high for Change in Receivables was $780000.0 in Q1 2021, with the low at -$616000.0 in Q4 2021.
- The 5-year median for Change in Receivables is -$39000.0 (2023), against an average of -$55699.6.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables slumped 2504.76% in 2023, then surged 9371.43% in 2025.
- Vyome Holdings' Change in Receivables stood at -$616000.0 in 2021, then surged by 96.59% to -$21000.0 in 2022, then plunged by 2504.76% to -$547000.0 in 2023, then grew by 9.77% to -$493532.0 in 2024, then soared by 37.74% to -$307293.0 in 2025.
- Business Quant data shows HIND's Change in Receivables at -$307293.0 in Q3 2025, $649000.0 in Q2 2025, and -$321000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -307,293.00 |
| Sep 30, 2025 | -307,293.00 |
| Jun 30, 2025 | 649,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Mar 31, 2025 | -321,000.00 |
| Mar 31, 2025 | -321,000.00 |
| Dec 31, 2024 | -493,532.00 |
| Dec 31, 2024 | -493,532.00 |
| Sep 30, 2024 | 380,532.00 |
| Sep 30, 2024 | 380,532.00 |
| Jun 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | -440,000.00 |
| Mar 31, 2024 | -440,000.00 |
| Dec 31, 2023 | -547,000.00 |
| Dec 31, 2023 | -547,000.00 |
| Sep 30, 2023 | 482,000.00 |
| Sep 30, 2023 | 482,000.00 |
| Jun 30, 2023 | -39,000.00 |
| Jun 30, 2023 | -39,000.00 |